Mary Price, MA

Articles

May 15th 2023

Tacking Upwind: Reducing Spending Among High-risk Commercially Insured Patients

Nicole M. Benson, MD, MBI Mary Price, MA Max Weiss, BA Christine Vogeli, PhD Maryann M. Vienneau, BS Mallika L. Mendu, MD, MBA Amy Flaster, MD, MBA Lisa Balentine, BASc Lindsay Jubelt, MD, MS Gregg S. Meyer, MD, MSc John Hsu, MD, MBA, MSCE

Although commercial accountable care organization populations are healthy on average, some individuals might benefit from programs for high-risk patients to mitigate high levels of health care utilization.

April 10th 2023

Population Turnover and Leakage in Commercial ACOs

Nicole M. Benson, MD, MBI Mary Price, MA Christine Vogeli, PhD Maryann M. Vienneau, BS Mallika L. Mendu, MD, MBA Amy Flaster, MD, MBA Lisa Balentine, BASc Lindsay Jubelt, MD, MS Gregg S. Meyer, MD, MSc John Hsu, MD, MBA, MSCE

Payment models that align financial incentives of payers, providers, and patients can mitigate spending growth in thoughtful ways, but the details of the models matter.

December 4th 2019

Delivery System Performance as Financial Risk Varies

Joseph P. Newhouse, PhD Mary Price, MA John Hsu, MD, MBA Bruce Landon, MD, MBA J. Michael McWilliams, MD, PhD

One delivery system’s healthcare utilization in its Medicare Advantage product was notably less than in its Pioneer accountable care organization or in a traditional Medicare comparison group.

January 20th 2016

The Introduction of Generic Risperidone in Medicare Part D

Vicki Fung, PhD Mary Price, MA Alisa B. Busch, MD, MS Mary Beth Landrum, PhD Bruce Fireman, MA Andrew A. Nierenberg, MD Joseph P. Newhouse, PhD John Hsu, MD, MBA, MSCE

This study examines the plan characteristics associated with generic risperidone use and spending and adherence outcomes associated with use among Medicare Advantage Part D beneficiaries.